Data updated: May 26, 2026
MEDICAL AIR, USP (medical air)
Trial Activity: Stable 2 active trials
Respiratory
Approved 2013-06-16
Development Insights
University Hospital, Tours conducting 2 trials (33%)
9 indications explored (Moderate)
→ suicidal ideation (1 trials)
→ emergency psychiatric (1 trials)
→ nitrous oxide (1 trials)
18
Indications
--
Phase 3 Trials
12
Years on Market
Details
- Status
- Prescription
- First Approved
- 2013-06-16
- Routes
- INHALATION
- Dosage Forms
- GAS
Companies
OXARC INC LINDE NORTH AMERICA INC AIR LIQUIDE AMERICA SPECIALITY GASES MACHINE & WELDING SUPPLY CO DUPUY OXYGEN WYNN L MADER, INDUSTRIAL GAS DISTRIBUTORS PURITY CYLINDER GASES, INC AIR LIQUIDE AMERICA LP AIRGAS USA LLC NEXAIR PRAXAIR DISTRIBUTION INC GENERAL SERVICES & SUPPLY CO SCOTT-GROSS COMPANY MATHESON TRI-GAS INC WESTAIR GASES & EQUIPMENT INC UNITED STATES WELDING INC LINDE GAS PUERTO RICO INC WSM SUPPLIER LLC PRAXAIR DISTRIBUTION MID-ATLANTIC LLC ACETYLENE OXYGENE CO AMERICAN WELDING AND GAS INC CENTRAL WELDING SUPPLY INDUSTRIAL WELDING SUPPLY CO OF HARVEY INC CEE KAY SUPPLY
Active Ingredient: MEDICAL AIR
Website: ↗
MEDICAL AIR, USP Approval History
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
24 FDA actions from 2013 to 2026
Jun 2013 ORIGINAL
Update
What MEDICAL AIR, USP Treats
18 FDA approvalsOriginally approved for its first indication in 2013 . Covers 18 distinct patient populations.
- Other (18)
Other
(18 approvals)- • Approved indication (Jun 2013)
- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Jul 2013)Letter
- • Approved indication (Aug 2013)Letter
- • Approved indication (Aug 2013)Letter
- • Approved indication (Aug 2013)Letter
- • Approved indication (Sep 2013)Letter
- • Approved indication (Apr 2014)Letter
- • Approved indication (May 2014)Letter
- • Approved indication (Dec 2015)Letter
- • Approved indication (Dec 2016)Letter
- • Approved indication (Dec 2017)Letter
- • Approved indication (Jul 2024)Letter
- • Approved indication (Feb 2026) NewLetter
📋
Clinical Trial Registry
6 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06430489 PROTORISC | DR230123 | Ph 2 | not yet recruiting | Treatment of Suicidal Ideation in the Emergency Department Using Nitrous Oxide |
| NCT06382389 PROTO-EHPAD | DR220204 2023-504691-18-00 | Ph 2 | not yet recruiting | Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial- |
| NCT02957851 ProtoTOP | ALMED-15-C2-054 | Ph 2 | completed | EMONO for the Treatment of Peripheral Neuropathic Pain |
| NCT01990404 MEOPA-PA | RC31/12/066 2012-004129-25 | Ph 2, Ph 3 | terminated | Efficacy of Premixed Nitrous Oxide and Oxygen in Elderly Patient With Out-of-hospital Severe Acute Pain |
| NCT01356745 MEOPA | 0900603 | Ph 4 | completed | Efficacy of Premixed Nitrous Oxide and Oxygen in Patient With Out-of-hospital Moderate Acute Pain |
| NCT02668029 | WalkO2 | Ph 2 | completed | Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
MEDICAL AIR, USP FDA Label Details
Track MEDICAL AIR, USP with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment